Caius Gabriel Radu

Professor, Molecular and Medical Pharmacology, University of California Los Angeles

Professor, Surgery, University of California Los Angeles

My group aims to advance the understanding of fundamental biological processes at the interface between metabolic and signal transduction networks in cancer, immune cells, and stromal cells and leverage this knowledge to develop new diagnostic and therapeutic approaches. We have established a highly integrated research program, including state-of-the-art instrumentation for both Positron Emission Tomography (PET) and Mass Spectrometry platforms (for metabolomics, proteomics, and phosphoproteomics), as well as an interdisciplinary team of investigators at UCLA and other institutions, with expertise in molecular imaging, cancer metabolism, immunobiology, signal transduction, structural biology, radiochemistry, medicinal chemistry, and virology. The potential of the program is demonstrated by recent work which uncovered a new role for the nucleoside salvage pathway in hematopoiesis, developed new PET probes for nucleotide metabolism, several of which have been successfully translated to the clinic, and discovered novel small molecule inhibitors of a metabolic kinase, from which a clinical candidate compound with low nanomolar affinity and oral bioavailability has emerged with indications in selected solid tumors and autoimmune disorders, and has entered Phase I clinical trials in Fall 2021. An additional area of research for my group concerns the immunobiology of pancreatic and prostate cancers. In this area, we seek to identify novel immunometabolic checkpoints that a) are governed by nucleosides and nucleotides, b) are interconnected with pattern recognition receptor and MAPK signaling pathways, and c) are amenable to pharmacological modulation alone or in combination with mutation-targeted therapies and immunotherapies. To facilitate the development of new therapies targeting these immunometabolic checkpoints, we are developing novel molecular imaging approaches capable of providing reliable pharmacodynamic biomarkers.

Interests

nucleotide metabolism, cancer immunobiology, molecular imaging, immunotherapy

Education and Training

University of California07/2006Postdoctoral training in cancer biology
UT Southwestern Medical Center07/2001Postdoctoral training in Immunology
University of MedicineMD07/1993
National CollegeBS07/1987Mathematics and Physics

Awards and Honors

  • Challenge Award, Prostate Cancer Foundation, 2019-2021.
  • Challenge Award, Prostate Cancer Foundation, 2017-2019.

Publications

  1. Ghukasyan R, Liang K, Chau K, Li L, Chan C, Abt ER, Le T, Park JY, Wu N, Premji A, Damoiseaux R, Luu T, Labora A, Rashid K, Link JM, Radu CG, Donahue TR. MEK inhibition sensitizes pancreatic cancer to STING agonism by tumor-cell intrinsic amplification of type I interferon signaling.. Clinical cancer research : an official journal of the American Association for Cancer Research, 2023.
  2. Labora A, Lee H, Chan C, Tabornal E, Le T, Rashid K, Abt E, Yamao T, Mandl H, Creech A, Premji A, Li L, Link J, Wu N, Radu C, Donahue T. Generation of liver metastases in a mouse model using ultrasound-guided intravenous injection.. STAR protocols, 2023.
  3. Lam AK, Roshan R, Miley W, Labo N, Zhen J, Kurland AP, Cheng C, Huang H, Teng PL, Harelson C, Gong D, Tam YK, Radu CG, Epeldegui M, Johnson JR, Zhou ZH, Whitby D, Wu TT. Immunization of Mice with Virus-Like Vesicles of Kaposi Sarcoma-Associated Herpesvirus Reveals a Role for Antibodies Targeting ORF4 in Activating Complement-Mediated Neutralization.. Journal of virology, 2023.
  4. Kemp SB, Cheng N, Markosyan N, Sor R, Kim IK, Hallin J, Shoush J, Quinones L, Brown NV, Bassett JB, Joshi N, Yuan S, Smith M, Vostrejs WP, Perez-Vale KZ, Kahn B, Mo F, Donahue TR, Radu CG, Clendenin C, Christensen JG, Vonderheide RH, Stanger BZ. Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer.. Cancer discovery, 2023.
  5. Guantay L, Garro C, Siri S, Pansa MF, Ghidelli-Disse S, Paviolo N, Racca A, Nicotra V, Radu C, Bocco JL, Felice R, Jansson KH, Remlinger K, Amador A, Stronach E, Coleman K, Muelbaier M, Drewes G, Gloger I, Madauss K, García M, Gottifredi V, Soria G. Deoxycytidine kinase (dCK) inhibition is synthetic lethal with BRCA2 deficiency.. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 2023.
  6. Chen BY, Salas JR, Trias AO, Perez Rodriguez A, Tsang JE, Guemes M, Le TM, Galic Z, Shepard HM, Steinman L, Nathanson DA, Czernin J, Witte ON, Radu CG, Schultz KA, Clark PM. Targeting deoxycytidine kinase improves symptoms in mouse models of multiple sclerosis.. Immunology, 2022.
  7. Abt ER, Rashid K, Le TM, Li S, Lee HR, Lok V, Li L, Creech AL, Labora AN, Mandl HK, Lam AK, Cho A, Rezek V, Wu N, Abril-Rodriguez G, Rosser EW, Mittelman SD, Hugo W, Mehrling T, Bantia S, Ribas A, Donahue TR, Crooks GM, Wu TT, Radu CG. Purine nucleoside phosphorylase enables dual metabolic checkpoints that prevent T cell immunodeficiency and TLR7-associated autoimmunity.. The Journal of clinical investigation, 2022.
  8. Le TM, Lee HR, Abt ER, Rashid K, Creech AL, Liang K, Cui J, Cho A, Wei L, Labora A, Chan C, Sanchez E, Kriti K, Karin D, Li L, Wu N, Mona C, Carlucci G, Hugo W, Wu TT, Donahue TR, Czernin J, Radu CG. 18F-FDG PET Visualizes Systemic STING Agonist-Induced Lymphocyte Activation in Preclinical Models.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2022.
  9. Aguilera KY, Le T, Riahi R, Lay AR, Hinz S, Saadat EA, Vashisht AA, Wohlschlegel J, Donahue TR, Radu CG, Dawson DW. Porcupine Inhibition Disrupts Mitochondrial Function and Homeostasis in WNT Ligand-Addicted Pancreatic Cancer.. Molecular cancer therapeutics, 2022.
  10. Li S, Yokota T, Wang P, Ten Hoeve J, Ma F, Le TM, Abt ER, Zhou Y, Wu R, Nanthavongdouangsy M, Rodriguez A, Wang Y, Lin YJ, Muranaka H, Sharpley M, Braddock DT, MacRae VE, Banerjee U, Chiou PY, Seldin M, Huang D, Teitell M, Gertsman I, Jung M, Bensinger SJ, Damoiseaux R, Faull K, Pellegrini M, Lusis AJ, Graeber TG, Radu CG, Deb A. Cardiomyocytes disrupt pyrimidine biosynthesis in nonmyocytes to regulate heart repair.. The Journal of clinical investigation, 2022.
  11. Abt ER, Le TM, Dann AM, Capri JR, Poddar S, Lok V, Li L, Liang K, Creech AL, Rashid K, Kim W, Wu N, Cui J, Cho A, Lee HR, Rosser EW, Link JM, Czernin J, Wu TT, Damoiseaux R, Dawson DW, Donahue TR, Radu CG. Reprogramming of nucleotide metabolism by interferon confers dependence on the replication stress response pathway in pancreatic cancer cells.. Cell reports, 2022.
  12. Liang K, Abt ER, Le TM, Cho A, Dann AM, Cui J, Li L, Rashid K, Creech AL, Wei L, Ghukasyan R, Rosser EW, Wu N, Carlucci G, Czernin J, Donahue TR, Radu CG. STING-driven interferon signaling triggers metabolic alterations in pancreas cancer cells visualized by [18F]FLT PET imaging.. Proceedings of the National Academy of Sciences of the United States of America, 2021.
  13. Czernin J, Radu C, Ribas A. Leadership Focus on Advancing Cancer Research and Treatment: A Conversation Between Johannes Czernin, Caius Radu, and Antoni Ribas.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2021.
  14. Moore AM, Zhou L, Cui J, Li L, Wu N, Yu A, Poddar S, Liang K, Abt ER, Kim S, Ghukasyan R, Khachatourian N, Pagano K, Elliott I, Dann AM, Riahi R, Le T, Dawson DW, Radu CG, Donahue TR. NAD+ depletion by type I interferon signaling sensitizes pancreatic cancer cells to NAMPT inhibition.. Proceedings of the National Academy of Sciences of the United States of America, 2021.
  15. Czernin J, Radu C. The Solutions Come from Science and Knowledge.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2020.
  16. Stuparu AD, Capri JR, Meyer CAL, Le TM, Evans-Axelsson SL, Current K, Lennox M, Mona CE, Fendler WP, Calais J, Eiber M, Dahlbom M, Czernin J, Radu CG, Lückerath K, Slavik R. Mechanisms of Resistance to Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy in a Mouse Model of Prostate Cancer.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2020.
  17. Czernin J, Current K, Mona CE, Nyiranshuti L, Hikmat F, Radu CG, Lückerath K. Immune-Checkpoint Blockade Enhances 225Ac-PSMA617 Efficacy in a Mouse Model of Prostate Cancer.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2020.
  18. Bicak M, Lückerath K, Kalidindi T, Phelps ME, Strand SE, Morris MJ, Radu CG, Damoiseaux R, Peltola MT, Peekhaus N, Ho A, Veach D, Malmborg Hager AC, Larson SM, Lilja H, McDevitt MR, Klein RJ, Ulmert D. Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted α-particle therapy.. Proceedings of the National Academy of Sciences of the United States of America, 2020.
  19. Sun DL, Poddar S, Pan RD, Rosser EW, Abt ER, Van Valkenburgh J, Le TM, Lok V, Hernandez SP, Song J, Li J, Turlik A, Chen X, Cheng CA, Chen W, Mona CE, Stuparu AD, Vergnes L, Reue K, Damoiseaux R, Zink JI, Czernin J, Donahue TR, Houk KN, Jung ME, Radu CG. Isoquinoline thiosemicarbazone displays potent anticancer activity with in vivo efficacy against aggressive leukemias.. RSC medicinal chemistry, 2020.
  20. Stuparu AD, Meyer CAL, Evans-Axelsson SL, Lückerath K, Wei LH, Kim W, Poddar S, Mona CE, Dahlbom M, Girgis MD, Radu CG, Czernin J, Slavik R. Targeted alpha therapy in a systemic mouse model of prostate cancer - a feasibility study.. Theranostics, 2020.
  21. Current K, Meyer C, Magyar CE, Mona CE, Almajano J, Slavik R, Stuparu AD, Cheng C, Dawson DW, Radu CG, Czernin J, Lueckerath K. Investigating PSMA-Targeted Radioligand Therapy Efficacy as a Function of Cellular PSMA Levels and Intratumoral PSMA Heterogeneity.. Clinical cancer research : an official journal of the American Association for Cancer Research, 2020.
  22. Kim SS, Xu S, Cui J, Poddar S, Le TM, Hayrapetyan H, Li L, Wu N, Moore AM, Zhou L, Yu AC, Dann AM, Elliott IA, Abt ER, Kim W, Dawson DW, Radu CG, Donahue TR. Histone deacetylase inhibition is synthetically lethal with arginine deprivation in pancreatic cancers with low argininosuccinate synthetase 1 expression.. Theranostics, 2020.
  23. Poddar S, Capparelli EV, Rosser EW, Gipson RM, Wei L, Le T, Jung ME, Radu C, Nikanjam M. Development and preclinical pharmacology of a novel dCK inhibitor, DI-87.. Biochemical pharmacology, 2019.
  24. Abt ER, Rosser EW, Durst MA, Lok V, Poddar S, Le TM, Cho A, Kim W, Wei L, Song J, Capri JR, Xu S, Wu N, Slavik R, Jung ME, Damoiseaux R, Czernin J, Donahue TR, Lavie A, Radu CG. Metabolic Modifier Screen Reveals Secondary Targets of Protein Kinase Inhibitors within Nucleotide Metabolism.. Cell chemical biology, 2019.
  25. Chen BY, Ghezzi C, Villegas B, Quon A, Radu CG, Witte ON, Clark PM. 18F-FAC PET Visualizes Brain-Infiltrating Leukocytes in a Mouse Model of Multiple Sclerosis.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2019.
  26. Zhu Y, Smith DJ, Zhou Y, Li YR, Yu J, Lee D, Wang YC, Di Biase S, Wang X, Hardoy C, Ku J, Tsao T, Lin LJ, Pham AT, Moon H, McLaughlin J, Cheng D, Hollis RP, Campo-Fernandez B, Urbinati F, Wei L, Pang L, Rezek V, Berent-Maoz B, Macabali MH, Gjertson D, Wang X, Galic Z, Kitchen SG, An DS, Hu-Lieskovan S, Kaplan-Lefko PJ, De Oliveira SN, Seet CS, Larson SM, Forman SJ, Heath JR, Zack JA, Crooks GM, Radu CG, Ribas A, Kohn DB, Witte ON, Yang L. Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer.. Cell stem cell, 2019.
  27. Plamthottam S, Sun D, Van Valkenburgh J, Valenzuela J, Ruehle B, Steele D, Poddar S, Marshalik M, Hernandez S, Radu CG, Zink JI. Activity and electrochemical properties: iron complexes of the anticancer drug triapine and its analogs.. Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry, 2019.
  28. Elliott IA, Dann AM, Xu S, Kim SS, Abt ER, Kim W, Poddar S, Moore A, Zhou L, Williams JL, Capri JR, Ghukasyan R, Matsumura C, Tucker DA, Armstrong WR, Cabebe AE, Wu N, Li L, Le TM, Radu CG, Donahue TR. Lysosome inhibition sensitizes pancreatic cancer to replication stress by aspartate depletion.. Proceedings of the National Academy of Sciences of the United States of America, 2019.
  29. Lückerath K, Wei L, Fendler WP, Evans-Axelsson S, Stuparu AD, Slavik R, Mona CE, Calais J, Rettig M, Reiter RE, Herrmann K, Radu CG, Czernin J, Eiber M. Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer.. EJNMMI research, 2018.
  30. Garrett M, Sperry J, Braas D, Yan W, Le TM, Mottahedeh J, Ludwig K, Eskin A, Qin Y, Levy R, Breunig JJ, Pajonk F, Graeber TG, Radu CG, Christofk H, Prins RM, Lai A, Liau LM, Coppola G, Kornblum HI. Metabolic characterization of isocitrate dehydrogenase (IDH) mutant and IDH wildtype gliomaspheres uncovers cell type-specific vulnerabilities.. Cancer & metabolism, 2018.
  31. Lückerath K, Stuparu AD, Wei L, Kim W, Radu CG, Mona CE, Calais J, Rettig M, Reiter RE, Czernin J, Slavik R, Herrmann K, Eiber M, Fendler WP. Detection Threshold and Reproducibility of 68Ga-PSMA11 PET/CT in a Mouse Model of Prostate Cancer.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2018.
  32. Antonios JP, Soto H, Everson RG, Moughon DL, Wang AC, Orpilla J, Radu C, Ellingson BM, Lee JT, Cloughesy T, Phelps ME, Czernin J, Liau LM, Prins RM. Detection of immune responses after immunotherapy in glioblastoma using PET and MRI.. Proceedings of the National Academy of Sciences of the United States of America, 2017.
  33. Le TM, Poddar S, Capri JR, Abt ER, Kim W, Wei L, Uong NT, Cheng CM, Braas D, Nikanjam M, Rix P, Merkurjev D, Zaretsky J, Kornblum HI, Ribas A, Herschman HR, Whitelegge J, Faull KF, Donahue TR, Czernin J, Radu CG. ATR inhibition facilitates targeting of leukemia dependence on convergent nucleotide biosynthetic pathways.. Nature communications, 2017.
  34. Fendler WP, Stuparu AD, Evans-Axelsson S, Lückerath K, Wei L, Kim W, Poddar S, Said J, Radu CG, Eiber M, Czernin J, Slavik R, Herrmann K. Establishing 177Lu-PSMA-617 Radioligand Therapy in a Syngeneic Model of Murine Prostate Cancer.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2017.
  35. Nguyen AH, Elliott IA, Wu N, Matsumura C, Vogelauer M, Attar N, Dann A, Ghukasyan R, Toste PA, Patel SG, Williams JL, Li L, Dawson DW, Radu C, Kurdistani SK, Donahue TR. Histone deacetylase inhibitors provoke a tumor supportive phenotype in pancreatic cancer associated fibroblasts.. Oncotarget, 2017.
  36. Knezevic CE, Wright G, Rix LLR, Kim W, Kuenzi BM, Luo Y, Watters JM, Koomen JM, Haura EB, Monteiro AN, Radu C, Lawrence HR, Rix U. Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets.. Cell chemical biology, 2016.
  37. Barrio MJ, Spick C, Radu CG, Lassmann M, Eberlein U, Allen-Auerbach M, Schiepers C, Slavik R, Czernin J, Herrmann K. Human Biodistribution and Radiation Dosimetry of 18F-Clofarabine, a PET Probe Targeting the Deoxyribonucleoside Salvage Pathway.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2016.
  38. Ribas V, Drew BG, Zhou Z, Phun J, Kalajian NY, Soleymani T, Daraei P, Widjaja K, Wanagat J, de Aguiar Vallim TQ, Fluitt AH, Bensinger S, Le T, Radu C, Whitelegge JP, Beaven SW, Tontonoz P, Lusis AJ, Parks BW, Vergnes L, Reue K, Singh H, Bopassa JC, Toro L, Stefani E, Watt MJ, Schenk S, Akerstrom T, Kelly M, Pedersen BK, Hewitt SC, Korach KS, Hevener AL. Skeletal muscle action of estrogen receptor α is critical for the maintenance of mitochondrial function and metabolic homeostasis in females.. Science translational medicine, 2016.
  39. Laks DR, Ta L, Crisman TJ, Gao F, Coppola G, Radu CG, Nathanson DA, Kornblum HI. Inhibition of Nucleotide Synthesis Targets Brain Tumor Stem Cells in a Subset of Glioblastoma.. Molecular cancer therapeutics, 2016.
  40. Kim W, Le TM, Wei L, Poddar S, Bazzy J, Wang X, Uong NT, Abt ER, Capri JR, Austin WR, Van Valkenburgh JS, Steele D, Gipson RM, Slavik R, Cabebe AE, Taechariyakul T, Yaghoubi SS, Lee JT, Sadeghi S, Lavie A, Faull KF, Witte ON, Donahue TR, Phelps ME, Herschman HR, Herrmann K, Czernin J, Radu CG. [18F]CFA as a clinically translatable probe for PET imaging of deoxycytidine kinase activity.. Proceedings of the National Academy of Sciences of the United States of America, 2016.
  41. Minkovsky A, Sahakyan A, Bonora G, Damoiseaux R, Dimitrova E, Rubbi L, Pellegrini M, Radu CG, Plath K. A high-throughput screen of inactive X chromosome reactivation identifies the enhancement of DNA demethylation by 5-aza-2'-dC upon inhibition of ribonucleotide reductase.. Epigenetics & chromatin, 2015.
  42. Kollareddy M, Dimitrova E, Vallabhaneni KC, Chan A, Le T, Chauhan KM, Carrero ZI, Ramakrishnan G, Watabe K, Haupt Y, Haupt S, Pochampally R, Boss GR, Romero DG, Radu CG, Martinez LA. Regulation of nucleotide metabolism by mutant p53 contributes to its gain-of-function activities.. Nature communications, 2015.
  43. McCracken MN, Radu CG. Targeted noninvasive imaging of the innate immune response.. Proceedings of the National Academy of Sciences of the United States of America, 2015.
  44. Nomme J, Li Z, Gipson RM, Wang J, Armijo AL, Le T, Poddar S, Smith T, Santarsiero BD, Nguyen HA, Czernin J, Alexandrova AN, Jung ME, Radu CG, Lavie A. Structure-guided development of deoxycytidine kinase inhibitors with nanomolar affinity and improved metabolic stability.. Journal of medicinal chemistry, 2014.
  45. Bunimovich YL, Nair-Gill E, Riedinger M, McCracken MN, Cheng D, McLaughlin J, Radu CG, Witte ON. Deoxycytidine kinase augments ATM-Mediated DNA repair and contributes to radiation resistance.. PloS one, 2014.
  46. Mosessian S, Duarte-Vogel SM, Stout DB, Roos KP, Lawson GW, Jordan MC, Ogden A, Matter C, Sadeghi S, Mills GQ, Schelbert HR, Radu CG, Czernin J, Couto M, Phelps ME. INDs for PET molecular imaging probes-approach by an academic institution.. Molecular imaging and biology, 2014.
  47. Danilova N, Bibikova E, Covey TM, Nathanson D, Dimitrova E, Konto Y, Lindgren A, Glader B, Radu CG, Sakamoto KM, Lin S. The role of the DNA damage response in zebrafish and cellular models of Diamond Blackfan anemia.. Disease models & mechanisms, 2014.
  48. Chodon T, Comin-Anduix B, Chmielowski B, Koya RC, Wu Z, Auerbach M, Ng C, Avramis E, Seja E, Villanueva A, McCannel TA, Ishiyama A, Czernin J, Radu CG, Wang X, Gjertson DW, Cochran AJ, Cornetta K, Wong DJ, Kaplan-Lefko P, Hamid O, Samlowski W, Cohen PA, Daniels GA, Mukherji B, Yang L, Zack JA, Kohn DB, Heath JR, Glaspy JA, Witte ON, Baltimore D, Economou JS, Ribas A. Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma.. Clinical cancer research : an official journal of the American Association for Cancer Research, 2014.
  49. Nathanson DA, Armijo AL, Tom M, Li Z, Dimitrova E, Austin WR, Nomme J, Campbell DO, Ta L, Le TM, Lee JT, Darvish R, Gordin A, Wei L, Liao HI, Wilks M, Martin C, Sadeghi S, Murphy JM, Boulos N, Phelps ME, Faull KF, Herschman HR, Jung ME, Czernin J, Lavie A, Radu CG. Co-targeting of convergent nucleotide biosynthetic pathways for leukemia eradication.. The Journal of experimental medicine, 2014.
  50. Nomme J, Murphy JM, Su Y, Sansone ND, Armijo AL, Olson ST, Radu C, Lavie A. Structural characterization of new deoxycytidine kinase inhibitors rationalizes the affinity-determining moieties of the molecules.. Acta crystallographica. Section D, Biological crystallography, 2013.
  51. Escuin-Ordinas H, Elliott MW, Atefi M, Lee M, Ng C, Wei L, Comin-Anduix B, Montecino-Rodriguez E, Avramis E, Radu C, Sharp LL, Ribas A. PET imaging to non-invasively study immune activation leading to antitumor responses with a 4-1BB agonistic antibody.. Journal for immunotherapy of cancer, 2013.
  52. Wang J, Hwang K, Braas D, Dooraghi A, Nathanson D, Campbell DO, Gu Y, Sandberg T, Mischel P, Radu C, Chatziioannou AF, Phelps ME, Christofk H, Heath JR. Fast metabolic response to drug intervention through analysis on a miniaturized, highly integrated molecular imaging system.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2013.
  53. Murphy JM, Armijo AL, Nomme J, Lee CH, Smith QA, Li Z, Campbell DO, Liao HI, Nathanson DA, Austin WR, Lee JT, Darvish R, Wei L, Wang J, Su Y, Damoiseaux R, Sadeghi S, Phelps ME, Herschman HR, Czernin J, Alexandrova AN, Jung ME, Lavie A, Radu CG. Development of new deoxycytidine kinase inhibitors and noninvasive in vivo evaluation using positron emission tomography.. Journal of medicinal chemistry, 2013.
  54. Gil JS, Machado HB, Campbell DO, McCracken M, Radu C, Witte ON, Herschman HR. Application of a rapid, simple, and accurate adenovirus-based method to compare PET reporter gene/PET reporter probe systems.. Molecular imaging and biology, 2013.
  55. Herrmann K, Dahlbom M, Nathanson D, Wei L, Radu C, Chatziioannou A, Czernin J. Evaluation of the Genisys4, a bench-top preclinical PET scanner.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2013.
  56. Amaraesekera B, Marchis PD, Bobinski KP, Radu CG, Czernin J, Barrio JR, Michael van Dam R. High-pressure, compact, modular radiosynthesizer for production of positron emitting biomarkers.. Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine, 2013.
  57. Vatakis DN, Bristol GC, Kim SG, Levin B, Liu W, Radu CG, Kitchen SG, Zack JA. Using the BLT humanized mouse as a stem cell based gene therapy tumor model.. Journal of visualized experiments : JoVE, 2012.
  58. Austin WR, Armijo AL, Campbell DO, Singh AS, Hsieh T, Nathanson D, Herschman HR, Phelps ME, Witte ON, Czernin J, Radu CG. Nucleoside salvage pathway kinases regulate hematopoiesis by linking nucleotide metabolism with replication stress.. The Journal of experimental medicine, 2012.
  59. Aarntzen EH, Srinivas M, Radu CG, Punt CJ, Boerman OC, Figdor CG, Oyen WJ, de Vries IJ. In vivo imaging of therapy-induced anti-cancer immune responses in humans.. Cellular and molecular life sciences : CMLS, 2012.
  60. Yaghoubi SS, Campbell DO, Radu CG, Czernin J. Positron emission tomography reporter genes and reporter probes: gene and cell therapy applications.. Theranostics, 2012.
  61. Lee JT, Campbell DO, Satyamurthy N, Czernin J, Radu CG. Stratification of nucleoside analog chemotherapy using 1-(2'-deoxy-2'-18F-fluoro-β-D-arabinofuranosyl)cytosine and 1-(2'-deoxy-2'-18F-fluoro-β-L-arabinofuranosyl)-5-methylcytosine PET.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2012.
  62. Vatakis DN, Koya RC, Nixon CC, Wei L, Kim SG, Avancena P, Bristol G, Baltimore D, Kohn DB, Ribas A, Radu CG, Galic Z, Zack JA. Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells.. Proceedings of the National Academy of Sciences of the United States of America, 2011.
  63. Campbell DO, Yaghoubi SS, Su Y, Lee JT, Auerbach MS, Herschman H, Satyamurthy N, Czernin J, Lavie A, Radu CG. Structure-guided engineering of human thymidine kinase 2 as a positron emission tomography reporter gene for enhanced phosphorylation of non-natural thymidine analog reporter probe.. The Journal of biological chemistry, 2011.
  64. Benz MR, Czernin J, Allen-Auerbach MS, Dry SM, Sutthiruangwong P, Spick C, Radu C, Weber WA, Tap WD, Eilber FC. 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography for response assessment in soft tissue sarcoma: a pilot study to correlate imaging findings with tissue thymidine kinase 1 and Ki-67 activity and histopathologic response.. Cancer, 2011.
  65. Ma C, Fan R, Ahmad H, Shi Q, Comin-Anduix B, Chodon T, Koya RC, Liu CC, Kwong GA, Radu CG, Ribas A, Heath JR. A clinical microchip for evaluation of single immune cells reveals high functional heterogeneity in phenotypically similar T cells.. Nature medicine, 2011.
  66. Ng QK, Su H, Armijo AL, Czernin J, Radu CG, Segura T. Clustered Arg-Gly-Asp peptides enhances tumor targeting of nonviral vectors.. ChemMedChem, 2011.
  67. Schwarzenberg J, Radu CG, Benz M, Fueger B, Tran AQ, Phelps ME, Witte ON, Satyamurthy N, Czernin J, Schiepers C. Human biodistribution and radiation dosimetry of novel PET probes targeting the deoxyribonucleoside salvage pathway.. European journal of nuclear medicine and molecular imaging, 2010.
  68. Zheng X, Yu CL, Sha W, Radu C, Huang SC, Feng D. Study of an image-derived SUV and a modified SUV using mouse FDG-PET.. Nuclear medicine and biology, 2010.
  69. Rabinovich BA, Radu CG. Imaging adoptive cell transfer based cancer immunotherapy.. Current pharmaceutical biotechnology, 2010.
  70. Koya RC, Mok S, Comin-Anduix B, Chodon T, Radu CG, Nishimura MI, Witte ON, Ribas A. Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses.. Proceedings of the National Academy of Sciences of the United States of America, 2010.
  71. Shu CJ, Campbell DO, Lee JT, Tran AQ, Wengrod JC, Witte ON, Phelps ME, Satyamurthy N, Czernin J, Radu CG. Novel PET probes specific for deoxycytidine kinase.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2010.
  72. Nair-Gill E, Wiltzius SM, Wei XX, Cheng D, Riedinger M, Radu CG, Witte ON. PET probes for distinct metabolic pathways have different cell specificities during immune responses in mice.. The Journal of clinical investigation, 2010.
  73. Mikkola HK, Radu CG, Witte ON. Targeting leukemia stem cells.. Nature biotechnology, 2010.
  74. Ribas A, Benz MR, Allen-Auerbach MS, Radu C, Chmielowski B, Seja E, Williams JL, Gomez-Navarro J, McCarthy T, Czernin J. Imaging of CTLA4 blockade-induced cell replication with (18)F-FLT PET in patients with advanced melanoma treated with tremelimumab.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2010.
  75. Laing RE, Nair-Gill E, Witte ON, Radu CG. Visualizing cancer and immune cell function with metabolic positron emission tomography.. Current opinion in genetics & development, 2010.
  76. Brewer S, Nair-Gill E, Wei B, Chen L, Li X, Riedinger M, Campbell DO, Wiltzius S, Satyamurthy N, Phelps ME, Radu C, Witte ON, Braun J. Epithelial uptake of [18F]1-(2'-deoxy-2'-arabinofuranosyl) cytosine indicates intestinal inflammation in mice.. Gastroenterology, 2010.
  77. Guo D, Cloughesy TF, Radu CG, Mischel PS. AMPK: A metabolic checkpoint that regulates the growth of EGFR activated glioblastomas.. Cell cycle (Georgetown, Tex.), 2010.
  78. Toy G, Austin WR, Liao HI, Cheng D, Singh A, Campbell DO, Ishikawa TO, Lehmann LW, Satyamurthy N, Phelps ME, Herschman HR, Czernin J, Witte ON, Radu CG. Requirement for deoxycytidine kinase in T and B lymphocyte development.. Proceedings of the National Academy of Sciences of the United States of America, 2009.
  79. Kottyan LC, Collier AR, Cao KH, Niese KA, Hedgebeth M, Radu CG, Witte ON, Khurana Hershey GK, Rothenberg ME, Zimmermann N. Eosinophil viability is increased by acidic pH in a cAMP- and GPR65-dependent manner.. Blood, 2009.
  80. Kwong GA, Radu CG, Hwang K, Shu CJ, Ma C, Koya RC, Comin-Anduix B, Hadrup SR, Bailey RC, Witte ON, Schumacher TN, Ribas A, Heath JR. Modular nucleic acid assembled p/MHC microarrays for multiplexed sorting of antigen-specific T cells.. Journal of the American Chemical Society, 2009.
  81. Guo D, Hildebrandt IJ, Prins RM, Soto H, Mazzotta MM, Dang J, Czernin J, Shyy JY, Watson AD, Phelps M, Radu CG, Cloughesy TF, Mischel PS. The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis.. Proceedings of the National Academy of Sciences of the United States of America, 2009.
  82. Yu ZT, Kamei K, Takahashi H, Shu CJ, Wang X, He GW, Silverman R, Radu CG, Witte ON, Lee KB, Tseng HR. Integrated microfluidic devices for combinatorial cell-based assays.. Biomedical microdevices, 2009.
  83. Laing RE, Walter MA, Campbell DO, Herschman HR, Satyamurthy N, Phelps ME, Czernin J, Witte ON, Radu CG. Noninvasive prediction of tumor responses to gemcitabine using positron emission tomography.. Proceedings of the National Academy of Sciences of the United States of America, 2009.
  84. Wang H, Wang S, Su H, Chen KJ, Armijo AL, Lin WY, Wang Y, Sun J, Kamei K, Czernin J, Radu CG, Tseng HR. A supramolecular approach for preparation of size-controlled nanoparticles.. Angewandte Chemie (International ed. in English), 2009.
  85. Shu CJ, Radu CG, Shelly SM, Vo DD, Prins R, Ribas A, Phelps ME, Witte ON. Quantitative PET reporter gene imaging of CD8+ T cells specific for a melanoma-expressed self-antigen.. International immunology, 2008.
  86. Wei LH, Olafsen T, Radu C, Hildebrandt IJ, McCoy MR, Phelps ME, Meares C, Wu AM, Czernin J, Weber WA. Engineered antibody fragments with infinite affinity as reporter genes for PET imaging.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2008.
  87. Radu CG, Shu CJ, Nair-Gill E, Shelly SM, Barrio JR, Satyamurthy N, Phelps ME, Witte ON. Molecular imaging of lymphoid organs and immune activation by positron emission tomography with a new [18F]-labeled 2'-deoxycytidine analog.. Nature medicine, 2008.
  88. Tumeh PC, Radu CG, Ribas A. PET imaging of cancer immunotherapy.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2008.
  89. Prins RM, Shu CJ, Radu CG, Vo DD, Khan-Farooqi H, Soto H, Yang MY, Lin MS, Shelly S, Witte ON, Ribas A, Liau LM. Anti-tumor activity and trafficking of self, tumor-specific T cells against tumors located in the brain.. Cancer immunology, immunotherapy : CII, 2008.
  90. Nair-Gill ED, Shu CJ, Radu CG, Witte ON. Non-invasive imaging of adaptive immunity using positron emission tomography.. Immunological reviews, 2008.
  91. Peter C, Waibel M, Radu CG, Yang LV, Witte ON, Schulze-Osthoff K, Wesselborg S, Lauber K. Migration to apoptotic "find-me" signals is mediated via the phagocyte receptor G2A.. The Journal of biological chemistry, 2007.
  92. McLaughlin J, Cheng D, Singer O, Lukacs RU, Radu CG, Verma IM, Witte ON. Sustained suppression of Bcr-Abl-driven lymphoid leukemia by microRNA mimics.. Proceedings of the National Academy of Sciences of the United States of America, 2007.
  93. Huang JH, Cárdenas-Navia LI, Caldwell CC, Plumb TJ, Radu CG, Rocha PN, Wilder T, Bromberg JS, Cronstein BN, Sitkovsky M, Dewhirst MW, Dustin ML. Requirements for T lymphocyte migration in explanted lymph nodes.. Journal of immunology (Baltimore, Md. : 1950), 2007.
  94. Bailey RC, Kwong GA, Radu CG, Witte ON, Heath JR. DNA-encoded antibody libraries: a unified platform for multiplexed cell sorting and detection of genes and proteins.. Journal of the American Chemical Society, 2007.
  95. Radu CG, Shu CJ, Shelly SM, Phelps ME, Witte ON. Positron emission tomography with computed tomography imaging of neuroinflammation in experimental autoimmune encephalomyelitis.. Proceedings of the National Academy of Sciences of the United States of America, 2007.
  96. Yang LV, Radu CG, Roy M, Lee S, McLaughlin J, Teitell MA, Iruela-Arispe ML, Witte ON. Vascular abnormalities in mice deficient for the G protein-coupled receptor GPR4 that functions as a pH sensor.. Molecular and cellular biology, 2006.
  97. Radu CG, Cheng D, Nijagal A, Riedinger M, McLaughlin J, Yang LV, Johnson J, Witte ON. Normal immune development and glucocorticoid-induced thymocyte apoptosis in mice deficient for the T-cell death-associated gene 8 receptor.. Molecular and cellular biology, 2006.
  98. Shu CJ, Guo S, Kim YJ, Shelly SM, Nijagal A, Ray P, Gambhir SS, Radu CG, Witte ON. Visualization of a primary anti-tumor immune response by positron emission tomography.. Proceedings of the National Academy of Sciences of the United States of America, 2005.
  99. Wang L, Radu CG, Yang LV, Bentolila LA, Riedinger M, Witte ON. Lysophosphatidylcholine-induced surface redistribution regulates signaling of the murine G protein-coupled receptor G2A.. Molecular biology of the cell, 2005.
  100. Radu CG, Nijagal A, McLaughlin J, Wang L, Witte ON. Differential proton sensitivity of related G protein-coupled receptors T cell death-associated gene 8 and G2A expressed in immune cells.. Proceedings of the National Academy of Sciences of the United States of America, 2005.
  101. Yang LV, Radu CG, Wang L, Riedinger M, Witte ON. Gi-independent macrophage chemotaxis to lysophosphatidylcholine via the immunoregulatory GPCR G2A.. Blood, 2004.
  102. Radu CG, Yang LV, Riedinger M, Au M, Witte ON. T cell chemotaxis to lysophosphatidylcholine through the G2A receptor.. Proceedings of the National Academy of Sciences of the United States of America, 2003.
  103. Deng C, Radu C, Diab A, Tsen MF, Hussain R, Cowdery JS, Racke MK, Thomas JA. IL-1 receptor-associated kinase 1 regulates susceptibility to organ-specific autoimmunity.. Journal of immunology (Baltimore, Md. : 1950), 2003.
  104. He XL, Radu C, Sidney J, Sette A, Ward ES, Garcia KC. Structural snapshot of aberrant antigen presentation linked to autoimmunity: the immunodominant epitope of MBP complexed with I-Au.. Immunity, 2002.